Omalizumab for prevention of anaphylactic episodes in a patient with severe mosquito allergy

Abstract Anaphylaxis after mosquito bite is rare, but life threatening. No approved preventive therapy is available to date, but omalizumab could be a promising therapeutic option for reducing risk and improving quality of life in these patients.

Guardado en:

Detalles Bibliográficos
Autores principales:	Elisa Meucci, Anna Radice, Filippo Fassio, Maria Loredana Chiara Iorno, Donatella Macchia
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	anaphylaxis mosquito allergy omalizumab Medicine R Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/5e76b6d89eee413f87ad7fef882ea071
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5e76b6d89eee413f87ad7fef882ea071
record_format	dspace
spelling	oai:doaj.org-article:5e76b6d89eee413f87ad7fef882ea0712021-12-02T07:55:57ZOmalizumab for prevention of anaphylactic episodes in a patient with severe mosquito allergy2050-090410.1002/ccr3.4935https://doaj.org/article/5e76b6d89eee413f87ad7fef882ea0712021-10-01T00:00:00Zhttps://doi.org/10.1002/ccr3.4935https://doaj.org/toc/2050-0904Abstract Anaphylaxis after mosquito bite is rare, but life threatening. No approved preventive therapy is available to date, but omalizumab could be a promising therapeutic option for reducing risk and improving quality of life in these patients.Elisa MeucciAnna RadiceFilippo FassioMaria Loredana Chiara IornoDonatella MacchiaWileyarticleanaphylaxismosquito allergyomalizumabMedicineRMedicine (General)R5-920ENClinical Case Reports, Vol 9, Iss 10, Pp n/a-n/a (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	anaphylaxis mosquito allergy omalizumab Medicine R Medicine (General) R5-920
spellingShingle	anaphylaxis mosquito allergy omalizumab Medicine R Medicine (General) R5-920 Elisa Meucci Anna Radice Filippo Fassio Maria Loredana Chiara Iorno Donatella Macchia Omalizumab for prevention of anaphylactic episodes in a patient with severe mosquito allergy
description	Abstract Anaphylaxis after mosquito bite is rare, but life threatening. No approved preventive therapy is available to date, but omalizumab could be a promising therapeutic option for reducing risk and improving quality of life in these patients.
format	article
author	Elisa Meucci Anna Radice Filippo Fassio Maria Loredana Chiara Iorno Donatella Macchia
author_facet	Elisa Meucci Anna Radice Filippo Fassio Maria Loredana Chiara Iorno Donatella Macchia
author_sort	Elisa Meucci
title	Omalizumab for prevention of anaphylactic episodes in a patient with severe mosquito allergy
title_short	Omalizumab for prevention of anaphylactic episodes in a patient with severe mosquito allergy
title_full	Omalizumab for prevention of anaphylactic episodes in a patient with severe mosquito allergy
title_fullStr	Omalizumab for prevention of anaphylactic episodes in a patient with severe mosquito allergy
title_full_unstemmed	Omalizumab for prevention of anaphylactic episodes in a patient with severe mosquito allergy
title_sort	omalizumab for prevention of anaphylactic episodes in a patient with severe mosquito allergy
publisher	Wiley
publishDate	2021
url	https://doaj.org/article/5e76b6d89eee413f87ad7fef882ea071
work_keys_str_mv	AT elisameucci omalizumabforpreventionofanaphylacticepisodesinapatientwithseveremosquitoallergy AT annaradice omalizumabforpreventionofanaphylacticepisodesinapatientwithseveremosquitoallergy AT filippofassio omalizumabforpreventionofanaphylacticepisodesinapatientwithseveremosquitoallergy AT marialoredanachiaraiorno omalizumabforpreventionofanaphylacticepisodesinapatientwithseveremosquitoallergy AT donatellamacchia omalizumabforpreventionofanaphylacticepisodesinapatientwithseveremosquitoallergy
_version_	1718399105680539648

Omalizumab for prevention of anaphylactic episodes in a patient with severe mosquito allergy

Ejemplares similares